SCHEMBL5145076

SCHEMBL5145076

O=S(=O)(NCC(Cc1ccc(Cl)cc1)c1ccc(Cl)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
TBXAS1 P24557 2/20 0.44
KMT2A Q03164 7/20 0.43
MEN1 O00255 6/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 3/20 0.43
CCR1 P32246 1/20 0.43
CYP19A1 P11511 1/20 0.42
LMNA P02545 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
XBP1 P17861 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5146619 0.89 CA1 (0.55) MAPTCA1CA2TBXAS1KMT2A
SCHEMBL5142978 0.85 CA1 (0.44) MAPTCA1CA2TBXAS1KMT2A
SCHEMBL5144858 0.85 PGR (0.50) MAPTKMT2AMEN1ALDH1A1CCR1
SCHEMBL5146505 0.83 MAPT (0.56) MAPTCA1CA2TBXAS1KMT2A
SCHEMBL5146860 0.80 PKM (0.43) MAPTCA1CA2KMT2AMEN1
SCHEMBL5146645 0.77 CA1 (0.51) MAPTCA1CA2TBXAS1KMT2A
SCHEMBL5146640 0.75 CNR1 (0.60)
SCHEMBL5144866 0.72 CNR1 (0.47) CA1CA2KMT2AMEN1ALDH1A1
SCHEMBL9312956 0.70 TBXAS1 (0.65) TBXAS1ALDH1A1POLBKDM4E
SCHEMBL9312019 0.70 TBXAS1 (0.57) TBXAS1ALDH1A1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663113-A4 SUBSTITUTED SULFONAMIDES MERCK & CO INC (US) 2007-06-13 EP claimed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US claimed
EP-1663113-A2 SUBSTITUTED SULFONAMIDES Merck & Co., Inc. (US) 2006-06-07 EP claimed
WO-2005027837-A2 SUBSTITUTED SULFONAMIDES MERCK & CO., INC. (US) 2005-03-31 WO claimed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed
US-20070105914-A1 Substituted sulfonamides MERCK SHARP & DOHME CORP. 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105914-A1 Substituted sulfonamides CNR2, CNR1, FAAH MAPT 2166/4885CA1 1216/4885CA2 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.